Bone health study for postmenopausal women
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This trial looks at bone health in women who have gone through menopause. It may help researchers understand more about osteoporosis (bone thinning) and how to treat it. You might be a fit if you are a postmenopausal woman aged 50-75 and have had a bone density scan at Kayseri City Hospital.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 50 and 75 years old.
- You have gone through menopause (no periods for at least a year).
- You had a bone density (DEXA) scan done at Kayseri City Hospital.
- Your bone thinning is NOT caused by another medical condition (like thyroid problems or long-term steroid use).
- You don't have any serious, uncontrolled health conditions.
- You have never had a bone fracture that happened without a clear cause.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well your blood vessels work and how strong your muscles are, in women after menopause with osteoporosis. You may be asked to start standard osteoporosis treatment, and the researchers will study pain and changes related to vascular function and sarcopenia (loss of muscle and strength).
This study tests two injectable medications (romosozumab and abaloparatide) that help strengthen bones in women after menopause. Researchers will also look at blood markers to understand why some women respond better to treatment than others.
This study looks at how bone strength (osteoporosis) and muscle mass (sarcopenia) are related in women who have passed menopause and are younger than 60. It aims to help understand and compare bone and muscle health in women with and without osteoporosis.
This trial tests whether a specific exercise program (circuit training) can improve bone density in women after menopause who have low bone mass. It may help strengthen bones and reduce fracture risk.
This study compares two treatment plans for women with osteoporosis to see which one improves hip bone density more. Participants will either get two medications in sequence (romosozumab followed by denosumab) or one medication (zoledronic acid), both given as injections or infusions. The goal is to find a treatment that reduces fracture risk.
This study looks at bone complications in women who have finished treatment with denosumab (a bone-strengthening drug) and aromatase inhibitors (hormone therapy for breast cancer). It aims to learn more about what happens to bones after stopping these medications, which may help guide future care.
Hear when a new Female Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.